Risedronate is in a class of drugs called bisphosphonates used for the treatment of Paget's disease of bone (in which the formation of bone is abnormal) and in persons with osteoporosis (in which the density and strength of bones are reduced).

The global Risedronate market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Risedronate volume and value at global level, regional level and company level. From a global perspective, this report represents overall Risedronate market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Merck
Amgen
Teva
Mylan
Apotex
Sanofi
Abbott
Novartis
Tecoland
Taj Pharmaceuticals

Segment by Regions
North America
Europe
China
Japan

Segment by Type
5 mg Tablets
35 mg Tablets
75 mg Tablets
150 mg Tablets

Segment by Application
Postmenopausal Osteoporosis
Men with Osteoporosis